Choosing a Safe Online Pharmacy: 2026 Compliance Guide

The five checks that tell you a pharmacy is safe

Before handing over payment or personal health information, run five checks on any UK online weight loss pharmacy. Each one takes under a minute. Together they tell you whether a provider is operating inside the UK's regulatory framework or outside it. The checks cover pharmacy registration, clinical regulation, medicine licensing, advertising compliance, and true annual cost.

1. Confirm the pharmacy is on the GPhC register

Every pharmacy in Great Britain must be registered with the General Pharmaceutical Council. You can search the register at pharmacyregulation.org by pharmacy name or registration number. The entry will show a named Superintendent Pharmacist, who is personally accountable for how the pharmacy is run. If a provider does not publish its GPhC number, or the name on the register does not match the trading name of the site, treat that as a warning.

2. Check the prescribing service is CQC-regulated

In England, clinical services that prescribe medicines online must be registered with the Care Quality Commission. This is a separate registration from the pharmacy itself. A pharmacy and its prescribing partner are usually two different organisations working together, and both must be properly regulated. Verify the prescribing partner at cqc.org.uk. Equivalent regulators cover Scotland (HIS), Wales (HIW), and Northern Ireland (RQIA).

3. Check that the medicines are MHRA-approved branded products

In the UK, only two GLP-1 medicines are licensed for weight management: Mounjaro (tirzepatide) and Wegovy (semaglutide). Both are manufactured by the original pharmaceutical companies (Eli Lilly and Novo Nordisk respectively) and supplied in sealed, branded pens. If a provider offers "compounded semaglutide," "generic tirzepatide," or unbranded pens, those products sit outside the UK's licensed medicines framework. In October 2025, the MHRA seized more than 2,000 unlicensed weight loss pens in what it described as the largest single seizure of trafficked weight loss medicines ever recorded by a law enforcement agency worldwide. The volume tells you this is not a one-off.

4. Search the ASA rulings database for the provider name

The Advertising Standards Authority publishes every upheld ruling at asa.org.uk/rulings. A single ruling is not necessarily disqualifying, but a pattern of rulings is worth weighing. You should also check the MHRA's published advertising investigations at gov.uk, where companies that have amended advertising after regulatory action are named.

5. Work out the true 12-month cost, not the headline monthly price

Weight loss treatment with a GLP-1 is a 12-month commitment, not a single-month purchase. Clinical trials show meaningful weight loss emerges over 52 to 68 weeks, and clinical guidance recommends continuing treatment in patients who are responding. The cost that matters is the total annual cost, which includes medication, service or prescribing fees, and delivery. A provider with a low headline monthly price and a service fee on every order can cost significantly more across 12 months than a provider with a higher headline price and a membership model that removes recurring fees.

The rules UK online weight loss pharmacies must follow

The UK regulates online weight loss pharmacies through four overlapping frameworks, each with a specific role. The GPhC regulates pharmacies. The CQC regulates clinical services that prescribe medicines. The MHRA regulates the medicines themselves, along with the advertising of prescription-only medicines. The ASA, through the CAP Code, regulates consumer-facing advertising across all media.

The most commonly misunderstood of these is the advertising rule. Under Rule 12.12 of the CAP Code and Part 14 of the Human Medicines Regulations 2012, prescription-only medicines cannot be advertised to the public in the UK. This applies to Mounjaro and Wegovy directly. It also applies to anything a reasonable consumer would understand as an advertisement for them. Since September 2025, the joint enforcement notice from the ASA, MHRA, and GPhC has been explicit: this includes language such as "weight loss injections," "obesity treatment jabs," or "GLP-1," as well as imagery depicting an injection pen, whether branded or unbranded. A landing page that features these elements counts as an advertisement for a POM even if the originating social media post did not.

This is why the inner pages of regulated pharmacy websites describe the service and the medical condition rather than the medicines themselves. It is not a stylistic choice. It is the law.

What the current enforcement picture shows

The UK regulatory regime for weight loss advertising has tightened sharply since early 2025. Between February and June 2025, the ASA monitored more than 20,000 paid-for adverts from 35 high-priority pharmacies. When monitoring began, 7% of ads were likely to breach the rules. By April 2025, after the first joint enforcement notice, that figure had fallen to 4%. By January 2026, after the second enforcement notice was published in September 2025, it stood at 1%.

The ASA has published 18 formal rulings on weight loss advertising since the start of 2025. The CAP Compliance team contacted 46 advertisers, instructing them to amend or remove non-compliant ads. In all but one case, advertisers agreed to do so. The single advertiser that did not respond was referred to the GPhC, and the investigation is ongoing at the time of writing.

For patients, the practical implication is simple. A provider that is still using banned language or injection pen imagery in 2026, after two joint enforcement notices and 18 published rulings, has either not been paying attention to the regulatory environment or has decided it does not apply to them. Neither answer is reassuring when the decision you are making is about who prescribes and dispenses a medicine you will be injecting for the next year.

How Foundry meets each standard

Foundry's regulatory position is a matter of public record, verifiable against each of the five checks above. The table below sets out the specific credential for each requirement, with the registration numbers and the prescribing partner named in full so that any reader can independently confirm them.

These are credentials, not claims. Every one of them can be independently checked before you make a decision.

Why the annual cost matters more than the monthly price

The clinical evidence for GLP-1 medicines in weight management comes from trials that ran for 68 weeks (STEP-1, semaglutide) and 72 weeks (SURMOUNT-1, tirzepatide). STEP-1 participants on semaglutide 2.4mg lost an average of 14.9% of body weight over 68 weeks. SURMOUNT-1 participants on tirzepatide 15mg lost an average of 22.5% over 72 weeks. In both trials, meaningful weight loss built progressively across the year. Stopping early means forgoing the results.

This matters for how you compare pharmacies. If you commit to 12 months of treatment, a £29 service fee on every order adds £348 across the year. Foundry's Forge annual membership replaces that with a single fee of £249, a saving of over 25% on service fees while keeping medication priced at cost.

For a member on Wegovy 0.25mg, the maths looks like this. On pay-as-you-go, the monthly cost is £89 (£60 medication plus £29 service fee), which works out to £1,068 across 12 months. On Forge membership, medication is £60 per month plus the £249 annual fee, giving a total of £969. For a member on Mounjaro 2.5mg, pay-as-you-go is £168 per month (£2,016 annually) and Forge is £139 per month plus £249 (£1,917 annually). The absolute annual saving of £99 is consistent across every dose, because the per-order service fee is flat.

The point is not that Foundry is the cheapest provider in every scenario. It is that a provider who prices for a month rather than a year is selling you something other than a clinical outcome.

Frequently asked questions